Monograph Details
|
|
Infections & Infestations
> Bacterial infections
|
|
SEPTRA I.V. INFUSION |
| Manufacturer |
|
King Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Sulfonamide + folic acid inhibitor. |
| Generic Name |
|
Sulfamethoxazole 80mg, trimethoprim 16mg; per mL; contains sulfites, benzyl alcohol. |
| Also |
• SEPTRA
• SEPTRA DS
• SEPTRA SUSPENSION
|
| Indications |
|
Susceptible Pneumocystis carinii pneumonia (PCP), shigellosis, severe or complicated UTIs. |
| Adults and Children |
|
Dilute (see literature); give IV over 60–90 minutes. <2months: not recommended. ≥2months: PCP: 15–20mg/kg per day (of trimethoprim) in 3–4 equal divided doses every 6–8 hours for up to 14 days. Shigellosis, UTIs: 8–10mg/kg per day (of trimethoprim) in 2–4 equal divided doses every 6, 8, or 12 hours for up to 5 days (for shigellosis) or up to 14 days (for UTIs). Max 60mL/day. |
| Contraindications |
|
Megaloblastic anemia due to folate deficiency. 3rd trimester pregnancy (Cat.C). Infants. Nursing mothers of ill, stressed, G6PD-deficient, premature, or hyperbilirubinemic infants. |
| Precautions |
|
Not for group A β-hemolytic strep. Avoid prolonged administration. Monitor blood, urine, and renal function. Hepatic or renal dysfunction. AIDS (increased risk of toxicity). Folate or G6PD deficiency. Allergy. Asthma (inj). Maintain adequate hydration. Discontinue if rash occurs. Elderly. CrCl 15–30mL/min: reduce dose by ½; CrCl <15mL/min: not recommended. |
| Interactions |
|
May potentiate oral anticoagulants, hypoglycemics, phenytoin, methotrexate. May increase risk of thrombocytopenic purpura with diuretics (esp. thiazides). May form insoluble precipitate with methenamine metabolites. |
| Adverse Reactions |
|
GI upset, allergic skin reactions, blood dyscrasias, hemolysis, hepatic or renal toxicity, crystalluria, pancreatitis, photosensitivity, drug fever, rash (may be serious, eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), lupus-like syndrome, peripheral neuritis, depression, convulsions, ataxia. |
| How Supplied |
Tabs—100
DS tabs—20, 100, 500
Susp—pt
Multidose vials (10mL, 20mL)—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
